The effect of tuberculin-induced secreted IL2 at baseline and patient age on BCG immunotherapy outcome
| Parameter | P | OR (95% CI) |
|---|---|---|
| IL2 secretion (Log10) | 0.003 | 0.018 (0.001–0.274) |
| Age | 0.832 | 1.009 (0.932–1.109) |
| Constant | 0.064 | 4,144.925 |
NOTE: A 10-fold increase in IL2 is associated with a 98.2% reduction in the odds of developing recurrence by 6 months. The model provided correct classification of individuals into remission and recurrence groups of 87.6%.